Elafibranor

Elafibranor

Clinical data
Other names	GFT505, SureCN815512
ATC code	None
Legal status
Legal status	Investigational
Identifiers
IUPAC name 2-[2,6 Dimethyl-4-[3-[4-(methylthio)phenyl]-3-oxo-1(E)-propenyl]phenoxyl]-2-methylpropanoic acid
CAS Number	923978-27-2
PubChem CID	9864881
ChemSpider	8040573
UNII	2J3H5C81A5
Chemical and physical data
Formula	C22H24O4S
Molar mass	384.49 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C(O)C(Oc1c(cc(cc1C)\C=C\C(=O)c2ccc(SC)cc2)C)(C)C
InChI InChI=1S/C22H24O4S/c1-14-12-16(13-15(2)20(14)26-22(3,4)21(24)25)6-11-19(23)17-7-9-18(27-5)10-8-17/h6-13H,1-5H3,(H,24,25)/b11-6+ Key:AFLFKFHDSCQHOL-IZZDOVSWSA-N

Elafibranor (INN, code name GFT505) is an experimental medication that is being studied and developed by Genfit for the treatment of cardiometabolic diseases including diabetes, insulin resistance, dyslipidemia, and non-alcoholic fatty liver disease (NAFLD).

Elafibranor is a dual PPARα/δ agonist.

See also

• MBX-8025
• Resveratrol
• Telmisartan

External links

• Genfit Pharmaceutical
• NashBiotechs Several articles on drug candidates in NASH